AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AstraZeneca, Ionis report major trial failure with heart disease drug" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Times, Barron's, Bloomberg.com and The Guardian. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 91d ago.
Quick answers
Why is "AstraZeneca, Ionis report major trial failure with heart disease drug" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Major drugmaker loses $27 billion in market value after failed trial MarketWatch · 91d ago
- AstraZeneca shares down as drug trial fails to meet target The Times · 91d ago
- AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction Barron's · 91d ago
- Watch AstraZeneca Drug Trial Failure Sends Shares Plunging Bloomberg.com · 91d ago
- Crude oil prices rise again while UK stock market falls, dragged down by AstraZeneca The Guardian · 91d ago
- AstraZeneca, Ionis report major trial failure with heart disease drug STAT · 91d ago
Topics
Related trends
AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D center
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Astra Doesn’t Need a Deal for Growth Beyond 2030, CEO Says
AstraZeneca asserts independence for post-2030 growth while investing over $1 billion in a new robotics-driven R&D hub in Cambridge, Massachusetts.
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
Otsuka and Ionis report positive Phase 3 FUSION trial data for ulefnersen in treating a rare genetic form of ALS.
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.